Skip to main content

RX Updates

Perspectives on the Safety of a JAK Inhibitor

Perspectives on the Safety of a JAK Inhibitor

Sponsored by AbbVie Medical Affairs
Addressing rheumatology patients’ needs: Drs. Pendleton Wickersham, Kevin Winthrop, and Christopher Ritchlin discuss benefit-risk of a JAK inhibitor in patients with RA, PsA, and AS. Long-term safety clinical trial data is also presented.
Dr Mease and Dr Armstrong

A Rheum & Derm Perspective on Treating PsA and Moderate-to-Severe PsO

Sponsored by Lilly USA
Dr. Mease and Dr. Armstrong discuss a multidisciplinary approach and important considerations when treating patients with joint and skin concerns. Ages 18+; for HCPs only.
Woman holding painful hand

Long-term JAK Inhibitor Treatment for Rheumatoid Arthritis (RA)

Sponsored by AbbVie Medical Affairs
Addressing RA patients’ needs: Dr. Len Calabrese discusses how to talk about treatment goals and benefit-risk with RA patients. Also, explore the long-term Phase 3 clinical trial data for a JAK inhibitor.
JaK Inhibitor Treatment

JAK Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response or Intolerance to TNF Inhibitors (TNFi-IR)

Sponsored by AbbVie Medical Affairs
Read for an overview of post hoc subgroup analysis results from TNF-IR RA patients in SELECT BEYOND, COMPARE, and CHOICE clinical trials of upadacitinib in RA patients…
Solving Still's Disease

Solving Still's Disease

RheumNow
Dr. Jack Cush reviews the history, manifestations, diagnosis and treatment of Still's disease.
Long Term JaK Inhibitor Thumbnail

Long-term JAK Inhibitor Treatment for Psoriatic Arthritis (PsA)

Sponsored by AbbVie Medical Affairs
Read for an overview of long-term results from SELECT-PsA 2, a clinical trial of oral upadacitinib vs. placebo in bDMARD-refractory PsA patients.
An Anti-IL-23 in Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis

An Anti-IL-23 in Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis

Sponsored by Janssen Biotech, Inc
Plaque psoriasis (PsO) and psoriatic arthritis (PsA) are disorders of the immune system driven primarily by dysregulated T cells. Studies suggest that the Interleukin (IL)-23/Th-17 axis is one of the pathways involved in the pathogenesis of PsO and PsA.
Expert Perspectives on SLE Pathophysiology and the Importance of Changing the Course of Disease

Expert Perspectives on SLE Pathophysiology and the Importance of Changing the Course of Disease

Sponsored by GSK US Medical Affairs
Leading experts from the SLE Educators' Network take us through the pathophysiology of SLE as we understand it today, and discuss the need to change the course of disease as a key treatment goal.
The Science Behind a JAK Inhibitor for the Treatment of Ankylosing Spondylitis(AS)

The Science Behind a JAK Inhibitor for the Treatment of Ankylosing Spondylitis(AS)

Sponsored by AbbVie Medical Affairs
Read for an overview of results from SELECT-AXIS 2, a clinical trial of oral upadacitinib vs. placebo in bDMARD-refractory AS patients.
PsA All the Way

The Future of PsA

RheumNow
As we conclude our PsA campaign, Dr. Ogdie shares information about Preventing PsA and Dr. Ritchlin discusses Future Discovery and Targets.
PsA Thumbnail

Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation

Sponsored by Novartis
Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Sponsored by Novartis Medical Affairs
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.
×